Page 143 - 2019_10 resto del Mondo_web

Meta-analysis of the impact of MRD in adult B-ALL
2016;172(3):392–400.
45. Bassan R, Spinelli O, Oldani E, et al.
Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation out- come in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J. 2014;4:e225.
46. Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123(24):3739–3749.
47. Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lym- phoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD study. Br J Haematol. 2008;142(2):227–237.
48. Patel B, Rai L, Buck G, et al. Minimal resid- ual disease is a significant predictor of treat- ment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2010;148(1):80–89.
49. Bassan R, Masciulli A, Spinelli O, et al. Enhanced survival in adult Philadelphia-neg- ative acute lymphoblastic leukemia (Ph- ALL) with an updated pediatric derived min- imal residual disease (MRD)/risk-specific treatment strategy: NILG Study 10. Haematologica. 2014;99(Suppl 1):S726.
50. Weng XQ, Shen Y, Sheng Y, et al. Prognostic significance of monitoring leukemia-associ- ated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia. Blood Cancer J. 2013;3:e133.
51. Yanada M, Sugiura I, Takeuchi J, et al. Prospective monitoring of BCR-ABL1 tran- script levels in patients with Philadelphia chromosome-positive acute lymphoblastic
leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol. 2008;143 (4):503–510.
52. Wetzler M, Watson D, Stock W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allo- geneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014;99(1):111–115.
53. Yoon JH, Park S, Jeon YW, et al. Comparable long-term outcomes of reduced-intensity and myeloablative conditioning allogeneic hematopoietic cell transplantation by mini- mal residual disease kinetics during the tyro- sine kinase inhibitor-based chemotherapy courses in adults with Philadelphia-chromo- some positive acute lymphoblastic leukemia in first remission. Blood. 2016;128(22):3979.
54. Lim S, Joo YD, Sohn SK. Serial monitoring of BCR-ABL by real-time polymerase chain reaction in newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia treated with imatinib. Haematologica. 2016;101(suppl 1):E856.
55. Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome- positive acute lymphoblastic leukemia. Blood. 2016;128(4):504–507.
56. Lussana F, Intermesoli T, Gianni F, et al. Achieving molecular remission before allo- geneic stem cell transplantation in adult patients with Philadelphia chromosome- positive acute lymphoblastic leukemia: Impact on relapse and long-term outcome. Blood Marrow Transplant. 2016;22(11): 1983–1987.
57. Stock W, Luger SM, Advani AD, et al. Favorable outcomes for older adolescents and young adults (AYA) with acute lym- phoblastic leukemia (ALL): early results of
U.S. Intergroup Trial C10403. Blood. 2014;
124 (21):796.
58. Bruggemann M, Raff T, Flohr T, et al.
Clinical significance of minimal residual dis- ease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3):1116–1123.
59. Dhèdin N, Huynh A, Maury S, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lym- phoblastic leukemia. Blood. 2015;125(16): 2486–2496.
60. Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chro- mosome-negative acute lymphoblastic leukemia in adolescents and adults accord- ing to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595–1604.
61. Bassan R, Masciulli A, Intermesoli T, et al. Final results of Northern Italy Leukemia Group (NILG) trial 10/07 combining pedi- atric-type therapy with minimal residual disease study and risk-oriented hematopoi- etic cell transplantation in adult acute lym- phoblastic leukemia (ALL). Blood. 2016;128 (22):176.
62. Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-precursor acute lym- phoblastic leukemia. Blood. 2018;131(14): 1522–1531.
63. Amgen Inc. BLINCYTO prescribing infor- mation. 2018. Available from: https://www.accessdata.fda.gov/drugsatf- da_docs/label/2018/125557s013lbl.pdf (Accessed 01 May 2018).
64. Herold T, Gokbuget N. Philadelphia-like acute lymphoblastic leukemia in adults. Curr Oncol Rep. 2017;19(5):31.
haematologica | 2019; 104(10)
2039